Business Context and Reporting Period
This Form 8-K reports on the results of the 2020 Annual Meeting of Stockholders held by Madrigal Pharmaceuticals, Inc. on June 17, 2020. The meeting was conducted virtually via Internet webcast. As of the record date of April 24, 2020, the company had 15,429,154 shares of common stock outstanding, with 14,339,286 shares present or represented by proxy, constituting a quorum.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting outcomes rather than financial performance.
Material Changes
No material financial changes are reported in this filing. The document details the successful election of directors and the ratification of the independent auditor.
Guidance, Outlook, and Voting Results
The filing details the final voting results for three proposals submitted to stockholders:
- Proposal No. 1 (Election of Directors): Stockholders elected three Class I nominees to the Board of Directors for a three-year term expiring in 2023.
- Paul A. Friedman, M.D.: 11,237,483 votes For; 680,239 votes Withheld.
- Kenneth M. Bate: 10,223,285 votes For; 1,694,464 votes Withheld.
- James M. Daly: 10,197,153 votes For; 1,720,569 votes Withheld.
- Proposal No. 2 (Ratification of Auditors): Stockholders ratified the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2020.
- Votes For: 14,334,506
- Votes Against: 4,175
- Votes Abstaining: 605
- Proposal No. 3 (Executive Compensation): Stockholders approved, on an advisory basis, the compensation of the named executive officers.
- Votes For: 11,799,778
- Votes Against: 93,291
- Votes Abstaining: 24,653
Investor Verification Checklist
- Verify the specific terms of the three-year directorships for the newly elected Class I nominees.
- Confirm the engagement letter details with PricewaterhouseCoopers LLP for the 2020 fiscal year.
- Review the Proxy Statement for detailed breakdowns of executive compensation referenced in Proposal No. 3.
- Note that 2,421,564 broker non-votes were recorded for the director election and executive compensation proposals.